A phase II clinical trial evaluating the preventive effectiveness of Lactobacillus vaginal suppositories in patients with recurrent cystitis

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Urinary tract infections (UTIs) are the most common bacterial infections in women, and many patients experience frequent recurrence. The aim of this report is to introduce an on-going prospective phase II clinical trial performed to evaluate the preventive effectiveness of Lactobacillus vaginal suppositories for prevention of recurrent cystitis. Patients enrolled in this study are administered vaginal suppositories containing the GAI 98322 strain of Lactobacillus crispatus every 2 days or 3 times a week for one year. The primary endpoint is recurrence of cystitis and the secondary endpoints are adverse events. Recruitment began in December 2013 and target sample size is 20 participants.

Original languageEnglish
Pages (from-to)299-302
Number of pages4
JournalActa Medica Okayama
Volume70
Issue number4
Publication statusPublished - 2016

Fingerprint

Suppositories
Phase II Clinical Trials
Cystitis
Lactobacillus
Recurrence
Bacterial Infections
Urinary Tract Infections
Sample Size
Lactobacillus crispatus

Keywords

  • Lactobacilli
  • Lactobacillus crispatus
  • Probiotics
  • Urinary tract infection
  • Vaginal suppository

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

@article{f91fa4f0ab0442308aa608838ce1e1c2,
title = "A phase II clinical trial evaluating the preventive effectiveness of Lactobacillus vaginal suppositories in patients with recurrent cystitis",
abstract = "Urinary tract infections (UTIs) are the most common bacterial infections in women, and many patients experience frequent recurrence. The aim of this report is to introduce an on-going prospective phase II clinical trial performed to evaluate the preventive effectiveness of Lactobacillus vaginal suppositories for prevention of recurrent cystitis. Patients enrolled in this study are administered vaginal suppositories containing the GAI 98322 strain of Lactobacillus crispatus every 2 days or 3 times a week for one year. The primary endpoint is recurrence of cystitis and the secondary endpoints are adverse events. Recruitment began in December 2013 and target sample size is 20 participants.",
keywords = "Lactobacilli, Lactobacillus crispatus, Probiotics, Urinary tract infection, Vaginal suppository",
author = "Koichiro Wada and Shinya Uehara and Ayano Ishii and Takuya Sadahira and Masumi Yamamoto and Ritsuko Mitsuhata and Atsushi Takamoto and Motoo Araki and Yasuyuki Kobayashi and Masami Watanabe and Toyohiko Watanabe and Katsuyuki Hotta and Yasutomo Nasu",
year = "2016",
language = "English",
volume = "70",
pages = "299--302",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "4",

}

TY - JOUR

T1 - A phase II clinical trial evaluating the preventive effectiveness of Lactobacillus vaginal suppositories in patients with recurrent cystitis

AU - Wada, Koichiro

AU - Uehara, Shinya

AU - Ishii, Ayano

AU - Sadahira, Takuya

AU - Yamamoto, Masumi

AU - Mitsuhata, Ritsuko

AU - Takamoto, Atsushi

AU - Araki, Motoo

AU - Kobayashi, Yasuyuki

AU - Watanabe, Masami

AU - Watanabe, Toyohiko

AU - Hotta, Katsuyuki

AU - Nasu, Yasutomo

PY - 2016

Y1 - 2016

N2 - Urinary tract infections (UTIs) are the most common bacterial infections in women, and many patients experience frequent recurrence. The aim of this report is to introduce an on-going prospective phase II clinical trial performed to evaluate the preventive effectiveness of Lactobacillus vaginal suppositories for prevention of recurrent cystitis. Patients enrolled in this study are administered vaginal suppositories containing the GAI 98322 strain of Lactobacillus crispatus every 2 days or 3 times a week for one year. The primary endpoint is recurrence of cystitis and the secondary endpoints are adverse events. Recruitment began in December 2013 and target sample size is 20 participants.

AB - Urinary tract infections (UTIs) are the most common bacterial infections in women, and many patients experience frequent recurrence. The aim of this report is to introduce an on-going prospective phase II clinical trial performed to evaluate the preventive effectiveness of Lactobacillus vaginal suppositories for prevention of recurrent cystitis. Patients enrolled in this study are administered vaginal suppositories containing the GAI 98322 strain of Lactobacillus crispatus every 2 days or 3 times a week for one year. The primary endpoint is recurrence of cystitis and the secondary endpoints are adverse events. Recruitment began in December 2013 and target sample size is 20 participants.

KW - Lactobacilli

KW - Lactobacillus crispatus

KW - Probiotics

KW - Urinary tract infection

KW - Vaginal suppository

UR - http://www.scopus.com/inward/record.url?scp=84984801395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984801395&partnerID=8YFLogxK

M3 - Article

VL - 70

SP - 299

EP - 302

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 4

ER -